Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Little Green PharmaASX:LGP -3.95% Debt-to-EBITDA is 1.59 as of Mar. 2026. The stock has 3 warning signs investors should review. Among 689 Drug Manufacturers companies, Little Green Pharma ranks worse than 50.94% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Little Green Pharma's Debt-to-EBITDA or its related term are showing as below:
ASX:LGP'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -6.29 Med: -0.67 Max: 1.73
Current: 1.73
During the past 7 years, the highest Debt-to-EBITDA Ratio of Little Green Pharma was 1.73. The lowest was -6.29. And the median was -0.67.
ASX:LGP's Debt-to-EBITDA is ranked worse than 50.94% of 689
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs ASX:LGP: 1.73
Little Green Pharma (ASX:LGP) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Little Green Pharma Debt-to-EBITDA Related Terms
Little Green Pharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Little Green Pharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Little Green Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Little Green Pharma Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Little Green Pharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Little Green Pharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Little Green Pharma (ASX:LGP) has a Debt-to-EBITDA of 1.59 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Little Green Pharma. According to the industry distribution chart, Little Green Pharma ranks #351 out of 689 companies in the Drug Manufacturers industry, placing it in the top 50.9%.
Is Little Green Pharma's Debt-to-EBITDA too high?
Little Green Pharma's current Debt-to-EBITDA is 1.59. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. Little Green Pharma's value of 1.59 is 5.4% below this industry median. Based on the distribution chart, Little Green Pharma ranks #351 out of 689 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Little Green Pharma's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Little Green Pharma ranks #351 out of 689 companies for Debt-to-EBITDA. This places Little Green Pharma in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. Little Green Pharma's value of 1.59 is 5.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Little Green Pharma's current Debt-to-EBITDA of 1.59 is 5.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Little Green Pharma. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Little Green Pharma's current Debt-to-EBITDA is 1.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Little Green Pharma stock overvalued right now?
Based on GuruFocus' analysis, Little Green Pharma (ASX:LGP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.18, compared to a current price of A$0.07 — trading 59.4% below its estimated fair value. The current Debt-to-EBITDA is 1.59 and 5.4% below the Drug Manufacturers industry median of 1.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Little Green Pharma (ASX:LGP), the current Debt-to-EBITDA is 1.59 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets. The Group is organized into two operating segments: Australia and Europe (cultivation, production and distribution of cannabis products to Australian and European customers).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:LGP has been successfully added to your 
